Become a Member

Track your favourite stocks
Create & monitor portfolios
Daily portfolio value

Company	Chg	Chg %
Quickpicks
£	%
Add shares to your quickpicks to display them here!

Renalytix Plc (RENX) Share News

IN BRIEF: Renalytix chief business officer to become president

18th Apr 2024 11:20

Renalytix PLC - London-based diagnostics company focused on the management and testing of kidney disease through its KidneyIntelX platform - Chief Business Officer Howard Doran has been appointed as president, effective April 30. He replaces Thomas McLain, who is stepping down as president on the same date after serving in the role since July 2019. Doran has been business chief since September last year. Read More

UK shareholder meetings calendar - next 7 days

15th Apr 2024 14:09

IN BRIEF: Renalytix announces financing of up to USD4 million

8th Apr 2024 13:34

Renalytix PLC - London-based diagnostics company focused on the management and testing of kidney disease through its KidneyIntelX platform - Announces direct offer of shares at a purchase price equivalent to USD0.75 per NASDAQ American Depositary Share, or USD0.375 per common stock share, to DB Capital Partners Healthcare LP, an investor focused on innovative medical technology. Says the fundraise was conducted by way of a securities purchase agreement, consisting of an initial tranche of 2.7 million shares for USD1.0 million, and an optional subsequent tranche. If the optional tranche is exercised, Renalytix expects the total amount of financing to reach USD4 million. The price of USD0.375 per ordinary share represents a premium of roughly 4.1% to the company's closing price on Friday. Read More

TRADING UPDATES: Horizonte subsidiary hit with debt injunction

14th Mar 2024 18:26

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

IN BRIEF: Renalytix shares sink on heavily discounted placing

12th Mar 2024 13:59

Renalytix PLC - London-based diagnostics company focused on its flagship KidneyIntelX prognostic for patients with kidney disease - Launches placing for around USD10 million, or GBP7.8 million. The placing involves the issue of around 39 million shares in the company at a price of 20 pence each. This represents a roughly 28% discount to the company's Monday closing price of 38.54 pence per share. Renalytix says that issuing more than 20.0 million shares will require shareholder approval, which the company intends to seek at a general meeting, the date and time of which has yet to be confirmed. Read More

IN BRIEF: Renalytix shares up as company commences formal sale process

4th Mar 2024 13:56

Renalytix PLC - London-based diagnostics company, focused on prognosis services for patients with chronic kidney disease - Receives an unsolicited approach from a strategic acquiror which is evaluating a acquisition of the company's entire share capital. Renalytix describes the potential acquiror as a "large and well-capitalised publicly listed strategic diagnostics company". Renalytix has commenced a review of its options, including the sale of the company or its assets, and commenced a formal sale process. Renalytix says it may conclude that its interests are better served by other strategic options, including trading on AIM and Nasdaq as an independent entity, and therefore notes that there is no guarantee of the sale's completion. Read More

Renalytix up as kidneyintelX.dkd authorised for US government contract

29th Feb 2024 13:48

(Alliance News) - Renalytix PLC on Thursday said that the US government has approved its authorised text kidneyintelX.dkd, to its government-wide acquisition contract for early-stage kidney disease bioprognostic testing services. Read More

Renalytix narrows annual loss but cash balance and revenue fall

15th Feb 2024 11:35

(Alliance News) - Renalytix PLC shares dropped on Thursday as the company reported a reduced loss in a productive year, but with a depleted balance sheet. Read More

Renalytix up after US CMS issues draft local coverage determination

9th Feb 2024 10:36

(Alliance News) - Renalytix PLC on Friday reported another win for its flagship kidney disease test, pushing the company's shares up nearly 30%. Read More

Renalytix celebrates new data on KidneyIntelX for kidney disease

10th Jan 2024 14:52

(Alliance News) - Renalytix PLC on Wednesday published some data, which has demonstrated that KidneyIntelX has "broad implications for winning the war on chronic kidney disease." Read More

UK shareholder meetings calendar - next 7 days

8th Dec 2023 14:54

Renalytix shares dive as first quarter revenue halves

14th Nov 2023 11:38

(Alliance News) - Renalytix PLC on Tuesday said it was focused on cost reductions and sales growth as it reported a sharp drop in revenue. Read More

AIM WINNERS & LOSERS: Renalytix revenue halves; DP Poland trades well

14th Nov 2023 10:59

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday. Read More

UK earnings, trading statements calendar - next 7 days

7th Nov 2023 15:51

Renalytix hails US Patent Office allowing patent claims for IP

6th Oct 2023 11:04

(Alliance News) - Renalytix PLC on Friday said that the US Patent Office allowed its patent clams for intellectual property exclusively licensed to the company. Read More

AIM WINNERS & LOSERS: Safestyle plunges as seeks cash injection

3rd Oct 2023 10:21

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday. Read More

Renalytix says kidneyintelX.dkd test priced at USD950 by US Medicare

3rd Oct 2023 09:47

(Alliance News) - Renalytix PLC on Tuesday said the US Centers for Medicare & Medicaid services have published the price for kidneyintelX.dkd test. Read More

IN BRIEF: Renalytix annual loss narrows; optimistic on KidneyIntelX

28th Sep 2023 11:02

Renalytix PLC - London-based kidney health-focused diagnostics company - In the financial year to June 30, pretax loss narrows to USD46.2 million from USD49.6 million a year prior. Revenue grows 13% to USD3.4 million from USD3.0 million. Says that during financial 2023, over 5,000 KidneyIntelX tests were performed, up 55% annually. "We expect a meaningful increase in total tests during the remainder of fiscal 2024, building on quarterly test volumes of about 1,200 during fiscal 2023 and through first quarter of 2024. More than half of these during the first quarter of 2024 thus far are revenue generating, with a set of the Mount Sinai clinical trial tests no longer billable following last spring's transition to full commercial payment at the hospital system," the company says. Read More

IN BRIEF: Renalytix inks Texas contracts expanding insurance coverage

22nd Sep 2023 14:07

Renalytix PLC - London-based kidney health-focused diagnostics company - Says it has signed a contract with BlueCross and BlueShield of Texas to expand insurance coverage of KidneyIntelX in the state of Texas. Adds that it has executed a contract with Parkland Community Health Plan, a Dallas based insurance plan with over 300,000 covered lives and service in 7 counties, for insurance coverage of KidneyIntelX. Read More

TRADING UPDATES: Tintra receives bid approach; NCC trading in line

7th Sep 2023 20:27

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

FTSE 100 Latest

Value9,446.43

Change96.00